Lenacapavir submitted to the US FDA with an indication for HIV PrEP
20 December 2024. Related: Early access, Antiretrovirals, Treatment access, HIV prevention and transmission.
Antiretrovirals
Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48
26 November 2024. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine vs triple ART have similar efficacy in advanced HIV infection with CD4 <200 and viral load >100,000
21 November 2024. Related: Conference reports, Antiretrovirals.
Impact on CD4 counts of once-monthly islatravir in PrEP studies: early macaque results with MK-8527 follow-on compound
9 October 2024. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
AIDS 2024: Ten early reports
12 August 2024. Related: Conference reports, Antiretrovirals.
BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024
12 August 2024. Related: Antiretrovirals.
Five days on two days off: Biktarvy in pilot FOTO study
12 August 2024. Related: Conference reports, Antiretrovirals.
Subcutaneous formulation of long-acting CAB/RPV discontinued
10 August 2024. Related: Conference reports, Antiretrovirals.
First data on third-generation integrase inhibitor from ViiV
10 August 2024. Related: Conference reports, Antiretrovirals.
Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study
10 August 2024. Related: Conference reports, Antiretrovirals.
HIV pipeline: global overview for people in LMICs
11 July 2024. Related: Antiretrovirals, On the web.
Challenges with annual TAF implant
5 June 2024. Related: Conference reports, Antiretrovirals.
Drug resistance or side effects might limit ART in up to 1 in 10 people living with HIV
2 May 2024. Related: Antiretrovirals, Treatment strategies, Side effects, Drug resistance.
ART in early infection stops further viral evolution
21 April 2024. Related: Antiretrovirals, Virology.
Roche to discontinue enfuvirtide (T-20, Fuzeon)
24 March 2024. Related: Antiretrovirals.
CROI 2024: Pipeline ART – new drugs and formulations
19 March 2024. Related: Conference reports, Antiretrovirals.
CROI 2024: Promising results from first study of long-acting treatment in Africa
10 March 2024. Related: Conference reports, Antiretrovirals, Treatment access.
Five cases of viral failure on CAB-LA and RPV-LA injections
15 January 2024. Related: Antiretrovirals, Drug resistance.
EACS 2023: Switching to daily fixed-dose doravirine/islatravir: 96-week results
1 December 2023. Related: Conference reports, Antiretrovirals.
First-line ART drops below US $45 a year for low-income countries
1 December 2023. Related: Antiretrovirals, Treatment access.
Potential for monthly injectable: nanoformulated tenofovir/3TC/dolutegravir
1 December 2023. Related: Antiretrovirals.
IAS 2023: Lenacapavir studies at IAS: weekly oral dosing and baseline sensitivity in non-clade B settings
1 October 2023. Related: Conference reports, Antiretrovirals.
IAS 2023: LA-CAB/RPV as first-line ART and implementation studies
1 October 2023. Related: Conference reports, Antiretrovirals.
IAS 2023: bNAbs for prevention and cure: antiviral and vaccine-like responses
1 October 2023. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Cure-related research, Vaccines and microbicides.
Rapporteur summaries: track B clinical science
1 August 2023. Related: Conference reports, Antiretrovirals.
CAB-LA receives positive opinion for EU approval as PrEP
1 August 2023. Related: Antiretrovirals, HIV prevention and transmission.
ART increases life expectancy by 30 to 40 years: impact of CD4 count, sex and calendar year
1 June 2023. Related: Antiretrovirals, Treatment strategies, Ageing and life expectancy.
Generic versions of injectable PrEP could enable access to CAB-LA in low-income countries
6 April 2023. Related: Antiretrovirals, HIV prevention and transmission.
CROI 2023: Pipeline HIV drugs and formulations for treatment and PrEP
10 March 2023. Related: Conference reports, Antiretrovirals.
CROI 2023: Six-monthly ART – lenacapavir + dual bNAbs maintains undetectable viral load for 26 weeks after single doses
10 March 2023. Related: Conference reports, Antiretrovirals.
CROI 2023: Other lenacapavir studies – experienced and naive updates, the dosing window, HIV-2 and PrEP
10 March 2023. Related: Conference reports, Antiretrovirals.
CROI 2023: Similar PK profile for thigh vs gluteal CAB/RPV-LA injections: accidental intravenous injection
10 March 2023. Related: Conference reports, Antiretrovirals.
CROI 2023: Efficacy of N6LS monotherapy correlated with baseline factors
10 March 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: pipeline studies with bNAbs N6LS and maturation inhibitor GSK254
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: doravirine updates
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: long-acting cabotegravir/rilpivirine: adverse events, implementation and PROMs
1 February 2023. Related: Conference reports, Antiretrovirals.
Lenacapavir approved in the US for multidrug resistant HIV
1 February 2023. Related: Antiretrovirals.
More evidence for recycling tenofovir in second-line ART with dolutegravir: 72-week results from ARTIST study
1 February 2023. Related: Antiretrovirals, Treatment strategies.
Low level viral load on effective ART is linked to clonal expansion of reservoir: not affected by modifying ART
1 February 2023. Related: Antiretrovirals, Treatment strategies, Guidelines, Drug resistance.
Integrase inhibitors associated with higher increases in CD4:CD8 ratio than PI- or NNRTI-based ART
1 February 2023. Related: Antiretrovirals, Treatment strategies.
Glasgow 2022: Impact of islatravir on lymphocyte counts in a dose-ranging study: a post-hoc analysis
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Islatravir studies to use 0.25 mg daily dose to overcome risk of reducing CD4 and total lymphocytes
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Fostemsavir 240 week results from BRIGHTE study
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Fostemsavir: QT prolongation and drug-drug interactions
1 December 2022. Related: Conference reports, Antiretrovirals.
Early HIV diagnosis and treatment are important for better long-term health
1 December 2022. Related: Antiretrovirals.
EU recommends approval of dispersible abacavir/lamivudine/dolutegravir FDC for children weighing 14 to >25 kg
1 December 2022. Related: Antiretrovirals, Paediatric care.
AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3
3 October 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
Islatravir update: treatment studies to use a lower dose but PrEP research discontinued in favour of MK-8537
3 October 2022. Related: Antiretrovirals.
Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence
3 October 2022. Related: Antiretrovirals, Drug resistance.
Lenacapavir approved in the EU and UK to treat multidrug resistant HIV
1 September 2022. Related: Antiretrovirals.
Dolutegravir-based ART in children and adolescents: effective in six African countries
3 August 2022. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.
Early data on injecting CAB/RPV-LA into thigh muscle
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Simplifed lenacapavir dosing: PK results in HIV negative study
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Lenacapavir gets positive opinion for approval in the EU to treat MDR HIV
1 July 2022. Related: Antiretrovirals.
Combination bNAb’s sustain viral suppression for 40 weeks: phase 1 results
1 July 2022. Related: Antiretrovirals, Cure-related research.
Lenacapavir in MDR HIV: phase 3 results of CAPELLA study published
1 June 2022. Related: Antiretrovirals.
ViiV licenses long-acting cabotegravir (CAB-LA) for generic access
1 June 2022. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
FDA approves dispersible dolutegravir/abacavir/3TC for children
2 May 2022. Related: Antiretrovirals.
Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits
2 May 2022. Related: Antiretrovirals, Treatment access.
CROI 2022: Islatravir studies for HIV treatment and PrEP
1 April 2022. Related: Conference reports, Antiretrovirals.
US FDA removes need for oral lead-in with long-acting cabotegravir/rilpivirine injections: indication expanded to adolescents
1 April 2022. Related: Antiretrovirals.
CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Injectable CAB/RPV-LA results after three years follow-up
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
1 March 2022. Related: Conference reports, Antiretrovirals.